RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS. Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-molecule allosteric inhibitor, is effective in human cancer models bearing RAS–GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C). SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS–GTP loading. Our findings illuminate a critical function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS–GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS. SHP2 inhibition is a promising molecular therapeutic strategy for patients with cancers bearing these oncogenic drivers.Nichols et al. identify an SHP2 inhibitor that disrupts SOS1-mediated RAS–GTP loading with demonstrated efficacy in various types of tumour driven by mutant BRAF, NF1 or RAS.

• Publication year

  2018

• Venue

  Nature Cell Biology

• Publication date

  2018-07-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41556-018-0169-1PMID 30104724PMCID 6115280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

  2018cited by this paper
• Abstract 4877: Allosteric inhibition of SHP2 variants containing cancer-associated activating mutations

  2018cited by this paper
• Large-Scale Phosphoproteomics Reveals Shp-2 Phosphatase-Dependent Regulators of Pdgf Receptor Signaling

  2018cited by this paper
• Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

  2017cited by this paper
• A Braf kinase-inactive mutant induces lung adenocarcinoma

  2017cited by this paper
• Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

  2017cited by this paper
• In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer

  2017cited by this paper
• Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients

  2017cited by this paper
• Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.

  2016cited by this paper
• Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

  2016cited by this paper
• Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

  2016cited by this paper
• Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

  2016cited by this paper
• MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

  2015cited by this paper
• Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer

  2015cited by this paper
• Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

  2015cited by this paper
• BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.

  2015cited by this paper
• Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions.

  2015cited by this paper
• Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

  2015cited by this paper
• Comprehensive molecular profiling of lung adenocarcinoma

  2014cited by this paper
• Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

  2014cited by this paper
• The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

  2014cited by this paper
• Oncogenic K-Ras requires activation for enhanced activity

  2014cited by this paper
• PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

  2014cited by this paper
• Regulation of Hypoxia-inducible Factor 1α (HIF-1α) by Lysophosphatidic Acid Is Dependent on Interplay between p53 and Krüppel-like Factor 5*

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• Abstract 4289: 3-Dimensional growth reveals KRAS dependency.

  2013cited by this paper
• Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

  2013cited by this paper
• Fiji: an open-source platform for biological-image analysis

  2012cited by this paper
• Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines*

  2012cited by this paper
• Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

  2012cited by this paper
• Vemurafenib: the first drug approved for BRAF-mutant cancer

  2012cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival

  2010cited by this paper
• Multiple Decisive Phosphorylation Sites for the Negative Feedback Regulation of SOS1 via ERK*

  2010cited by this paper
• Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation

  2010cited by this paper
• The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.

  2008cited by this paper
• The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways

  2007cited by this paper
• The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways

  2007cited by this paper
• GEFs and GAPs: critical elements in the control of small G proteins.

  2007cited by this paper
• MAP kinase signalling pathways in cancer

  2007cited by this paper
• Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

  2006cited by this paper
• Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia

  2005cited by this paper
• Germ-line and somatic PTPN11 mutations in human disease.

  2005cited by this paper
• Regulation of the Mitogen-activated Protein Kinase Signaling Pathway by SHP2*

  2002cited by this paper
• Requirement of SHP2 Binding to Grb2-associated Binder-1 for Mitogen-activated Protein Kinase Activation in Response to Lysophosphatidic Acid and Epidermal Growth Factor*

  2000cited by this paper
• Binding of Shp2 Tyrosine Phosphatase to FRS2 Is Essential for Fibroblast Growth Factor-Induced PC12 Cell Differentiation

  1998cited by this paper
• Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2

  1996cited by this paper
• Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway.

  1994cited by this paper
• Regulation of Hypoxia-inducible Factor 1 alpha (HIF-1 alpha) by Lysophosphatidic Acid Is Dependent on Interplay between p53 and Kruppel-like Factor 5

  year unknowncited by this paper

• Antitumor effects of LPM5140276 and its potential combination with SHP2 inhibition in KRASG12D-mutant cancer

  2026cites this paper
• Structural insights into the binding modes of SHP2 allosteric inhibitors

  2026cites this paper
• Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

  2026cites this paper
• Unravelling Resistance: Integrating Metabolism, Epigenetics, Immunology, and Proteostasis in Strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant Colorectal Cancer

  2026cites this paper
• Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.

  2026cites this paper
• Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

  2026cites this paper
• KRAS Inhibition in Pancreatic Ductal Adenocarcinoma

  2026cites this paper
• RAS mutation-specific responses to paralog- and state-selective RAS inhibitors.

  2025cites this paper
• Clinical Progress of Targeted KRAS Drugs Combined with Immune Checkpoint Inhibitors in the Treatment of Pancreatic Cancer

  2025cites this paper
• JAB-3312, a Potent Allosteric SHP2 Inhibitor that Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.

  2025cites this paper
• Functional Analysis of Rare RAS Variants of Unknown Significance

  2025cites this paper
• Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

  2025cites this paper
• Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies

  2025cites this paper
• RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors

  2025cites this paper
• Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas

  2025cites this paper
• Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors.

  2025cites this paper
• Regulation and function of insulin and insulin-like growth factor receptor signalling

  2025cites this paper
• In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C--mutant non-small cell lung cancer.

  2025cites this paper
• Response and Resistance to RAS Inhibition in Cancer.

  2025cites this paper
• Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging.

  2025cites this paper
• A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system

  2025cites this paper
• Elucidating the therapeutic potential of indazole derivative bindarit against K-ras receptor: An in-silico analysis using molecular dynamics exploration

  2025cites this paper
• RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer.

  2025cites this paper
• Pharmacological inhibition of RAS pathway alleviates spine deformity in a mouse model of neurofibromatosis type 1

  2025influential citation
• RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer

  2025cites this paper
• Molecular regulatory network of glycolytic reprogramming in hepatocellular carcinoma and its clinical implications

  2025cites this paper
• Synthetic Lethality of SHP2 and XIAP Suppresses Proliferation and Metastasis in KRAS‐mutant Nonsmall Cell Lung Cancer

  2025cites this paper
• Tuning insulin receptor signaling using de novo-designed agonists.

  2025cites this paper
• RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

  2025cites this paper
• LINC02167 stabilizes KSR1 mRNA in an m5C-dependent manner to regulate the ERK/MAPK signaling pathway and promotes colorectal cancer metastasis

  2025cites this paper
• Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities

  2025cites this paper
• Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020.

  2025cites this paper
• Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer.

  2025cites this paper
• Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance

  2025cites this paper
• Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer.

  2025cites this paper
• Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling.

  2025cites this paper
• SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway

  2025cites this paper
• Integrated multi-omics identify key signalling pathways for notochord lumenogenesis in ascidian Ciona savignyi

  2025cites this paper
• Post-Translational Modifications Remodel Proteome-Wide Ligandability

  2025cites this paper
• Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma

  2025cites this paper
• Targeting SHP2 with Natural Products: Exploring Saponin-Based Allosteric Inhibitors and Their Therapeutic Potential

  2025cites this paper
• Discovery of novel imidazo[2,1-b][1,3,4]thiadiazole analogs as fluorescent SHP2 inhibitors.

  2025cites this paper
• Mechanism of Action and Research Progress of Drugs Targeting KRAS G12-Mutant Tumors

  2025cites this paper
• TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma

  2024cites this paper
• The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations

  2024cites this paper
• KRAS, a New Target for Precision Medicine in Colorectal Cancer?

  2024cites this paper
• Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade

  2024cites this paper
• Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay

  2024cites this paper
• SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers

  2024cites this paper
• Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity

  2024cites this paper
• KRAS-driven Tumorigenesis and KRAS-driven Therapy in Pancreatic Adenocarcinoma.

  2024cites this paper
• Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies

  2024cites this paper
• Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors.

  2024cites this paper
• Targeting Hyperactive Ras Signaling in Pediatric Cancer.

  2024cites this paper
• Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer

  2024cites this paper
• A comprehensive overview of the molecular features and therapeutic targets in BRAF V600E ‐mutant colorectal cancer

  2024cites this paper
• Allosteric inhibition of the tyrosine phosphatase SHP2 enhances the anti-tumor immunity of interferon α through induction of caspase-1-mediated pyroptosis in renal cancer.

  2024cites this paper
• Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer

  2024cites this paper
• Targeting the RAS upstream and downstream signaling pathway for Cancer treatment.

  2024cites this paper
• Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules.

  2024cites this paper
• Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers

  2024cites this paper
• SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.

  2024cites this paper
• Atomic-scale mechanisms of GDP extraction by SOS1 in KRAS-G12 and KRAS-D12 oncogenes

  2024cites this paper
• A patent review of SHP2 allosteric inhibitors (2018-present)

  2024cites this paper
• Protein tyrosine phosphatases: emerging role in cancer therapy resistance

  2024cites this paper
• RAF and MEK Inhibitors in Non-Small Cell Lung Cancer

  2024cites this paper
• Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases

  2024cites this paper
• Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer

  2024cites this paper
• Combinatorial strategies to target RAS-driven cancers

  2024cites this paper
• From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

  2024cites this paper
• Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.

  2024cites this paper
• Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2).

  2024cites this paper
• Next-generation therapies for pancreatic cancer

  2024cites this paper
• New clinical trial design in precision medicine: discovery, development and direction

  2024cites this paper
• Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.

  2024cites this paper
• BRAF — a tumour-agnostic drug target with lineage-specific dependencies

  2024cites this paper
• SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

  2024cites this paper
• Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

  2024cites this paper
• Re-expression of epigenetically silenced PTPRR by histone acetylation sensitizes RAS-mutant lung adenocarcinoma to SHP2 inhibition

  2024cites this paper
• Preclinical translational platform of neuroinflammatory disease biology relevant to neurodegenerative disease

  2024cites this paper
• Single Ion Pair Is Essential for Stabilizing SHP2's Open Conformation.

  2024cites this paper
• Autophagic Regulation of Adipogenesis Through TP53INP2: Insights from In Silico and In Vitro Analysis

  2024cites this paper
• Discovery of 1H-pyrazolo[3,4-b]pyrazine derivatives as selective allosteric inhibitor of protein tyrosine phosphatase SHP2 for the treatment of KRASG12C-mutant non-small cell lung cancer

  2024cites this paper
• Targeting KRAS in cancer

  2024cites this paper
• State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies

  2024cites this paper
• Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential

  2024cites this paper
• Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment.

  2024cites this paper
• Study on SHP2 Conformational Transition and Structural Characterization of Its High-Potency Allosteric Inhibitors by Molecular Dynamics Simulations Combined with Machine Learning

  2024influential citation
• Cereblon-Based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.

  2024cites this paper
• Unraveling atomic-scale mechanisms of GDP extraction catalyzed by SOS1 in KRAS-G12 and KRAS-D12 oncogenes

  2024cites this paper
• Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance

  2024cites this paper
• Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors

  2024cites this paper
• First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

  2024cites this paper
• RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

  2024cites this paper
• Forkhead box D subfamily genes in colorectal cancer: potential biomarkers and therapeutic targets

  2024cites this paper
• Targeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance.

  2024cites this paper
• Promising natural products targeting protein tyrosine phosphatase SHP2 for cancer therapy

  2024cites this paper
• Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

  2024cites this paper
• Role of molecular biology in the management of pancreatic cancer

  2024cites this paper
• Synthesis, fluorescence properties of novel thiazolo[3,2-b][1,2,4]triazol derivatives as potent SHP2 inhibitors and its uses in sensing for Fe3+ and cell imaging

  2024cites this paper